IBM Q2 shortfall triggers Pomerantz investigation
Analysis based on 6 articles · First reported Jul 30, 2026 · Last updated Aug 07, 2026
IBM's stock suffered a significant single-day decline of over 25% following the disappointing earnings, reflecting investor concern about the company's performance and growth prospects. The securities investigation adds legal and reputational risk, potentially prolonging negative sentiment and increasing volatility for IBM shares.
IBM (IBM) reported disappointing second-quarter 2026 financial results on July 14, 2026, attributing the shortfall to weak Z performance and associated software stack, primarily in Transaction Processing. The company acknowledged it 'faltered' and failed to close numerous large deals on expected timelines. Following the announcement, IBM's stock price fell $73.16 per share, or 25.21%, to close at $217.07. Pomerantz LLP, a securities litigation firm, launched an investigation into whether IBM and certain officers/directors engaged in securities fraud or unlawful business practices. The investigation is ongoing, and investors are being solicited to join a potential class action.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard